✨
AI Summary
- Key commercial and regulatory developments in Japan's biopharma market for Q1.
- Important corporate divestments and new product approvals were covered.
- The impact of the Iran war on Japan's healthcare sector was analyzed.
Guests on This Episode
IH
Ian Haydock
1 podcast appearance
LT
Lisa Takagi
1 podcast appearance